STAT3 and liver disorder: More importantly, our data reveal that pharmaceutical inhibition of MKL1, STAT3, or TWIST1 using small-molecule compounds was paralleled by suppression of EndMT and attenuation of liver fibrosis (Fig. 6f), thus laying out the groundwork for the development of novel therapeutics to treat end-stage liver diseases.